Literature DB >> 3347140

Vasopressin neuropeptides and acquisition of heroin and cocaine self-administration in rats.

J M van Ree1, E M Burbach-Bloemarts, M Wallace.   

Abstract

The effect of the vasopressin neuropeptide des-glycinamide (Arg8)-vasopressin (DGAVP) on reducing the acquisition of intravenous heroin self-administration in rats was analyzed. When rats reduced in body weight were allowed to self-administer heroin for 1 h per day in the presence of a fixed time, non contingent food delivery schedule, it appeared that heroin intake was related in an orderly way to the unit dose of heroin delivered. DGAVP decreased heroin intake during days 4 and 5 of acquisition, especially when a high dose of heroin was delivered. DGAVP decreased heroin intake more effectively when rats were tested without the food delivery schedule and for 6 h instead of 1 h sessions per day. Structure activity relationship studies revealed that the peptide (pGlu4, Cyt6)AVP-(4-8) was the shortest active sequence mimicking the effect of DGAVP and that this peptide was somewhat more potent than DGAVP in this respect. The peptide (pGlu4,Cyt6)AVP-(4-9) increased the heroin intake of the rats. DGAVP and (pGlu4,Cyt6)-AVP-(4-8) also decreased cocaine intake of body weight reduced rats given the opportunity to self-administer cocaine intravenously in daily 6 h sessions. It is concluded that vasopressin neuropeptides may decrease the reinforcing efficacy of heroin and cocaine during acquisition of drug self-administration rather than interact with nutritional and environmental factors influencing drug taking behavior.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3347140     DOI: 10.1016/0024-3205(88)90565-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Corticotropin-releasing factor receptor 2-deficiency eliminates social behaviour deficits and vulnerability induced by cocaine.

Authors:  Nadège Morisot; Romain Monier; Catherine Le Moine; Mark J Millan; Angelo Contarino
Journal:  Br J Pharmacol       Date:  2018-03-13       Impact factor: 8.739

2.  Arginine vasopressin gene expression changes within the nucleus accumbens during environment elicited cocaine-conditioned response in rats.

Authors:  E Rodríguez-Borrero; F Rivera-Escalera; F Candelas; J Montalvo; W J Muñoz-Miranda; J R Walker; C S Maldonado-Vlaar
Journal:  Neuropharmacology       Date:  2009-07-09       Impact factor: 5.250

3.  Effect of cocaine sensitization prior to pregnancy on maternal care and aggression in the rat.

Authors:  Benjamin C Nephew; Marcelo Febo
Journal:  Psychopharmacology (Berl)       Date:  2010-01-26       Impact factor: 4.530

Review 4.  Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic effects.

Authors:  Mariana Rae; Mariana Lemos Duarte; Ivone Gomes; Rosana Camarini; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2021-05-21       Impact factor: 9.473

5.  Oxytocin reduces cocaine seeking and reverses chronic cocaine-induced changes in glutamate receptor function.

Authors:  Luyi Zhou; Wei-Lun Sun; Amy B Young; Kunhee Lee; Jacqueline F McGinty; Ronald E See
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

6.  Effects of cocaine on maternal behavior and neurochemistry.

Authors:  Benjamin C Nephew; Marcelo Febo
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

7.  Enhanced upregulation of CRH mRNA expression in the nucleus accumbens of male rats after a second injection of methamphetamine given thirty days later.

Authors:  Jean Lud Cadet; Christie Brannock; Bruce Ladenheim; Michael T McCoy; Irina N Krasnova; Elin Lehrmann; Kevin G Becker; Subramaniam Jayanthi
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

8.  Cocaine sensitization increases kyphosis and modulates neural activity in adult nulliparous rats.

Authors:  Benjamin C Nephew; Martha K Caffrey; Ada C Felix-Ortiz; Marcelo Febo
Journal:  Brain Sci       Date:  2012-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.